From Maruti to Sun Pharma: These 4 stocks will fill in flight, sale call on Indusind Bank | Share Market Top Stocks Brokerage Reports Maruti Swiggy Sun Pharma Indusind Bank

Veteran brokerage firm Goldman Sachs has advised shopping by upgrading its ratings on Maruti. They believe that Maruti will benefit from GST cut and pricing strategy in entry-level car market. New models such as Victoris SUV and Evitara will intensify the growth of the company. The EPS estimate for FY26–28 has been increased by 12%. Goldman says that Maruti has a lower CO2 risk than peers and Cafe 3 is ready for regulation. This stock has a target of Rs 18,900.

Two brokerage on the swigy stock has been seen as extremely bullish. Morgan Stanley has given a target of Rs 450 by giving an overweight rating, while Nomura has set a target of Rs 550 with a BUY rating. Swiggy has strengthened the balance sheet by selling a steak of Rs 2,400 crore in Rapido. Apart from this, the company will benefit from transferring instamart business to subsidiary. After getting the IOCC status, Swiggy will become a completely Indian Ond and Controlled Company.

Goldman Sachs has given a neutral rating on Ashok Leyland and downgrade stock. Brokerage has given its target price of Rs 140. He says that after the recent boom, there is now Upside Limited. Margin reform and high-tanese mix shifts have already joined the stock price. Passenger car volumes can be ahead of CV in the next 12 months. However, a better performance in the LCV segment is expected.

Brokerage firm Jefferies has given the opinion of shopping on Sunpharma. Its target price is Rs 2,070. According to the report, Specialty Business has played an important role in improving the company’s margins in the last five years. Although the major impact of new drugs Leqselvi and Unloxcyt will not appear before FY26, new plants (HALOL and Mohali) will reduce the company’s risk.